Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Sen. Herb Kohl (D-Wis.) said on Wednesday he is investigating plans by Genentech (DNA) to limit the availability of Avastin bevacizumab to compounding pharmacies, which compound
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury